Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 3;22(1):114.
doi: 10.1186/s12887-022-03177-6.

Half-life time prediction of developing first-line antiretroviral treatment failure and its risk factors among TB and HIV co-infected children in Northwest Ethiopia; multi setting historical follow-up study

Ermias Sisay Chanie  1 , Achenef Asmamaw Muche  2 , Mengistu Berhanu Gobeza  3 , Eshetie Molla Alemu  4 , Wondimnew Desalegn Addis  4 , Melkalem Mamuye Azanaw  4 , Alemayehu Digssie Gebremariam  4 , Desalegn Tesfa  4 , Melaku Tadege Engidaw  4 , Getaneh Atikilit  4 , Sofonyas AbebawTiruneh  4 , Getachew Arage  5
Affiliations

Half-life time prediction of developing first-line antiretroviral treatment failure and its risk factors among TB and HIV co-infected children in Northwest Ethiopia; multi setting historical follow-up study

Ermias Sisay Chanie et al. BMC Pediatr. .

Abstract

Background: Even though treatment failure is higher among TB and HIV infected children in a resource-limited setting, there is no prior evidence in general and in the study area in particular. Hence, this study was aimed at determining the half-life time prediction of developing first-line antiretroviral treatment failure and its risk factors among TB and HIV co-infected children.

Methods: A historical follow-up study was employed among 239 TB and HIV co-infected children from January 2010-December 2020. The data was entered into Epi data version 4.2.2 and exported to STATA 14.0 Software for analysis. The Kaplan-Meier plot was used to estimate the half-life time to develop treatment failure. The required assumption was fulfilled for each predictor variable. Additionally, those variables having a p-value ≤0.25 in the bivariable analysis were fitted into a multivariable Cox-proportional hazards regression model. P-value, < 0.05 was used to declare a significant association.

Results: A total of 239 TB and HIV co-infected children were involved in this study. The overall half-life time to develop first treatment failure was found to be 101 months, with a total of 1027.8 years' follow-up period. The incidence rate and proportion of developing first-line treatment failure were 5.5 per 100 PPY (Person-Year) [CI (confidence interval): 3.7, 6.9] 100 PPY and 23.8% (CI; 18.8, 29.7) respectively. Factors such as hemoglobin 10 mg/dl [AHR (Adjusted Hazard Ratio): 3.2 (95% CI: 1.30, 7.73), severe acute malnutrition [AHR: 3.8 (95% CI: 1.51, 79.65), World Health Organization stage IV [AHR: 2.4 (95% CI: 1.15, 4.93)], and cotrimoxazole prophylaxis non user [AHR: 2.3 (95% CI: 1.14, 4.47)] were found to be a risk factor to develop treatment failure.

Conclusion: In this study, the half-life time to develop first-line treatment failure was found to be very low. In addition, the incidence was found to be very high. The presence of hemoglobin 10 mg/dl, severe acute malnutrition, World Health Organization stage, and non-use of cotrimoxazole prophylaxis were discovered to be risk factors for treatment failure. Further prospective cohort and qualitative studies should be conducted to improve the quality of care in paediatric ART clinics to reduce the incidence or burden of first line treatment failure among TB and HIV co-infected children.

Keywords: Children; Ethiopia; Half-life; TB and HIV co-infected; Treatment failure.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interest.

Figures

Fig. 1
Fig. 1
Kaplan mere curve shows the half-life time of developing First-line antiretroviral treatment failure among TB and HIV Co-infected Children in Northwest Ethiopia from September 2010-December 2020
Fig. 2
Fig. 2
Kaplan mere curve shows the predictor variable of developing First-line antiretroviral treatment failure among TB and HIV Co-infected Children in Northwest Ethiopia from September 2010-December 2020
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Fitzgerald F, Penazzato M, Gibb D. Development of antiretroviral resistance in children with HIV in low- and middle-income countries. J Infect Dis. 2013;207(suppl_2):S85–S92. doi: 10.1093/infdis/jit115. - DOI - PMC - PubMed
    1. Bacha T, Tilahun B, Worku A. Predictors of treatment failure and time to detection and switching in HIV-infected Ethiopian children receiving first line anti-retroviral therapy. BMC Infect Dis. 2012;12(1):1–8. doi: 10.1186/1471-2334-12-197. - DOI - PMC - PubMed
    1. Sisay MM, Ayele TA, Gelaw YA, Tsegaye AT, Gelaye KA, Melak MF. Incidence and risk factors of first-line antiretroviral treatment failure among human immunodeficiency virus-infected children in Amhara regional state, Ethiopia: a retrospective follow-up study. BMJ Open. 2018;8(4):e019181. doi: 10.1136/bmjopen-2017-019181. - DOI - PMC - PubMed
    1. Koye DN, Ayele TA, Zeleke BM. Predictors of mortality among children on antiretroviral therapy at a referral hospital, Northwest Ethiopia: a retrospective follow up study. BMC Pediatr. 2012;8(12):161. doi: 10.1186/1471-2431-12-161. - DOI - PMC - PubMed
    1. Workneh N, Girma T, Woldie M. Immunologic and clinical outcomes of children on HAART: a retrospective cohort analysis at Jimma University specialized hospital. Ethiop J Health Sci. 2009;19(2) Available from: https://www.ajol.info/index.php/ejhs/article/view/69422. [cited 2021 Jan 15].

MeSH terms

Substances